Zafrens uses nanofabrication technology to analyze and manipulate cells for drug discovery, integrating multiple disciplines to advance cellular analysis and drug development.

Zafrens

Zafrens | 2,161 followers on LinkedIn. Opening doors to new insights at the interface of biology, chemistry and engineering | Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Drug Hunter and Informatics Expert

Peter Nestler

Venture investor, Harvard professor, entrepreneur

Wasim Malik

Director, Software & Analytics at Zafrens

Steven Brown

Cofounder/Executive Director

Ravi Ramenani

"We think [this approach] to drug discovery and analysis where we miniaturize everything - we do high throughput experiments, but also high resolution experiments - will reveal insights that will allow us to try to democratize and make drug discovery simpler and cheaper" Swamy Vijayan, Founder & CEO Zafrens on Bio_Unlock Episode #002: The Future of Drug Discovery. Watch the full conversation here: https://lnkd.in/dXmDRds6 (or wherever you get your podcasts)

BlueYard Capital

Our CEO, Kandaswamy (Swamy) Vijayan recently joined a podcast Bio_Unlock hosted by BlueYard Capital , alongside Elliot Hershberg , author of the popular newsletter "Century of Biology". Swamy discussed his interdisciplinary approach that merges biology, chemistry, and engineering to understand and manipulate cell states. By miniaturizing experiments and screening at ultra-high throughput, Zafrens is challenging traditional drug discovery methods, enabling the study of thousands of cells simultaneously. Elliot shared insights into the evolution of biotech towards "tech bio," emphasizing the importance of engineering disciplines in revolutionizing biological research. They discussed the transformative potential of AI and machine learning in analyzing vast datasets and guiding experimental design. Thanks to Elliot, Anastasia, and BlueYard Capital for the insightful discussion! 🎙️ #Immunotherapy #Innovation #startup Direct link here: https://lnkd.in/dXmDRds6

We are excited to announce that our CEO Kandaswamy (Swamy) Vijayan will be joining a panel discussion at the Precision Medicine World Conference #PMWC24 next week! Register for the conference here: https://lnkd.in/gM_Xxdi7 Follow our page for future updates at Zafrens Are you interested in learning more about Zafrens or our recently launched Ultra High-Throughput Functional Genomics "Z-Screen" Platform? Leave a message at hello@zafrens.com PMWC - Precision Medicine World Conference , Tal Behar , #PMWC24

Thank you to Genetic Engineering & Biotechnology News (GEN) for speaking with our CEO Swamy Vijayan about Zafrens' $23M financing, as well as our partnering and growth plans! Please reach out to learn more about our exciting work to compress early drug discovery at a fraction of traditional costs by using 200,000 microwell arrays in place of 96 well plates. #drugdiscovery#pharma#biotech#financing#TCR#smallmolecule#bispecific#antibody#biologics#CAR-T#cell#therapy https://lnkd.in/db-Sg5m9

Hello, world! Happy to announce our financing and emergence from stealth. Please reach out if you feel we can work together!

msh id	COM:ZAFRENS
symbol	-
name	Zafrens
homepage url	https://www.zafrens.com
country	US
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	-
crunchbase url	https://www.crunchbase.com/organization/zafrens
linkedin url	https://www.linkedin.com/company/zafrens
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	1.9K
monthly webtraffic growth	-0.93
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

ZAFR

COM:ZAFRENS

Zafrens

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-